H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Raises Target Price to $10
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $11
Diamedica Therapeutics (DMAC) Gets a Buy From Lake Street
Diamedica Therapeutics Is Maintained at Buy by HC Wainwright & Co.
DiaMedica Therapeutics Analyst Ratings
Buy Rating for Diamedica Therapeutics Driven by Promising DM199 Developments and Upcoming Trial Results
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Raises Target Price to $11
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating